About
Overview
Company Leadership
Science
Technology Platform
Scientific Publications
Pipeline
Overview
CF101
CF102
CF602
Investor Information
Overview
News / Events
Company Information
Financial Information
Stock Information
SEC Filings
Corporate Governance
Shareholders Meetings
Contact Us
Directions
Investor Information
Overview
News / Events
Press Releases
In The News
Research
Events Calendar
Presentations
Email Alerts
Company Information
Profile
Management
IR Contacts
FAQ
Financial Information
Quarterly & Annual Reports
Stock Information
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Section 16 Filings
Corporate Governance
Board of Directors
Governance Docs
Shareholders Meetings
Email Alerts
IR Contacts
RSS News Feed
Press Releases
All News
By Year:
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Nov 29, 2019 7:00 AM EST
Can-Fite Reports Third Quarter 2019 Financial Results & Provides Clinical Update
Nov 21, 2019 7:00 AM EST
Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on November 25, 2019
Nov 19, 2019 7:00 AM EST
Can-Fite Granted Patents for its Sexual Dysfunction Drug
Nov 11, 2019 7:00 AM EST
Can-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, Positioning this Indication for Animal Health Market
Nov 4, 2019 7:00 AM EST
Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients
Oct 31, 2019 7:00 AM EDT
U.S. FDA Agreed with Can-Fite’s Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer
Oct 17, 2019 8:00 AM EDT
Can-Fite and Gebro Pharma holding European Conference on Development & Commercialization of Phase III Drug Candidate Piclidenoson in the Treatment of Rheumatoid Arthritis
Oct 16, 2019 7:00 AM EDT
Can-Fite BioPharma Interview to Air on Bloomberg International on the RedChip Money Report
Oct 15, 2019 6:30 AM EDT
Can-Fite Completes Patient Enrollment in Phase II NASH Study of Namodenoson™
Oct 10, 2019 7:00 AM EDT
Can Fite Announces Publication of Namodenoson™ NASH Mechanism of Action in International Journal of Molecular Medicine
<< Previous
1...
2
3
4
5
6
7
8
9
10
11
...30
Next >>
Show All